Microsoft word - cv_jvg-20080915_bl.doc

Consultant Clinical Management/Operational Research Supervision and support of clinical activities in the HIV program Providing advice and assistance in the organization of the HIV/ARV program Advanced training of the FHI team and health care staff in HIV care Development and implementation of an observational database Support for operational research activities Support for statistical analysis and publication of the AMATA study Medical Doctor ARV program – Operational Research/Program Documentation Médecins Sans Frontières OCB, Kigali, Rwanda July 2006 – Jan 2008 Expert advice on clinical management of ART Training of district doctors in HIV care Supervision of data management of the MSF Rwanda HIV cohort: adult cohort/pediatric Data analysis of the HIV/ARV cohort data Publication and documentation of the HIV/ARV program (analytical and descriptive Medical Doctor ARV program August 2005 - July 2006 Médecins Sans Frontières OCB, Kigali, Rwanda • Supervision of the clinical management of 3500 HIV-positive patients and the ARV • Training of health care providers in HIV/ART care • Organization and coordination of the comprehensive HIV program: capacity-building, task shifting, standardization and simplification within the ARV program • Integration of different services and programs Clinical Preceptor/HIV expert - Masa ARV Program, Botswana August 2004 - June 2005 African Comprehensive HIV/AIDS partnerships (ACHAP) via the Institute of Tropical Medicine, Antwerp, Belgium, http://www.achap.org • Training and supervision of the local multi-discipline ARV teams responsible for the • Providing advice and assistance in establishing and improving clinical care for patients • Theoretical training on HIV/AIDS and ARV for the hospital and clinic staff • Coordination of the ARV-related activities from the different departments and health • Assisting in the integration of support functions, disease management, and referrals in a SPECIALIST TRAINING IN INTERNAL MEDICINE SPECIALIST TRAINING IN INTERNAL MEDICINE Pretoria Academic Hospital, South-Africa PHD THESIS: Gene therapy of AIDS: Gene transfer of Antiretroviral Genes into Hematopoietic Stem Laboratory of Molecular Virology and Gene Therapy Distance Learning Program London University London School of Hygiene and Tropical Medicine MASTERS IN EPIDEMIOLOGY (Currently in Progress) Distance Learning Program London University London School of Hygiene and Tropical Medicine • Tropical Diseases, Catholic University Leuven, Belgium (1997) • Medical Biostatistics, Catholic University Leuven, Belgium (1999) • Seminars in Biostatistics, Catholic University Leuven, Belgium (2003) • Glaxo Grant for the Study in Infectiology and Clinical Microbiology (2000) Dutch (mother-tongue) English (fluent) French (fluent) Proficient in Word, PowerPoint, Access, Excel, SPSS, Stata 9.0, Epi-Info, EpiData, advanced internet user, Reference Manager, Endnote ORAL PRESENTATIONS AT SCIENTIFIC MEETINGS • Patient retention in pre-ART care at primary health centers in Rwanda. Fourth national HIV research conference, Rwanda, July 2008. • Toxicity of stavudine and nevirapine-containing antiretroviral treatment regimens. Fourth national HIV research conference, Rwanda, July 2008. • Validity of WHO-recommended immunological criteria for ARV treatment failure. PEPFAR International HIV Implementers Meeting, Rwanda June 2007. • Success and challenges of paediatric antiretroviral treatment: MSF experience in two urban health care centers in Kigali, Rwanda. Pre-conference International Symposium on Children Affected by HIV/AIDS, 16th International AIDS Conference, Toronto, August 2006. • Symptomatic lactic Acidaemia on stavudine-containing ART: Clinical features of 20 Cases and risk factor assessment. Third national HIV research conference, Rwanda, March 2007. • Validation of WHO-recommended immunological criteria for ARV treatment failure. Third national HIV research conference, Rwanda, March 2007. • Two year experience of HAART in adults: cohort analysis of in 2 urban health centers In Kigali, Rwanda. Second national HIV research Conference, Rwanda, 2006. • Overexpression of HIV-1 integrase in CEM cells interferes with HIV-1 replication: a potential new gene therapeutic approach for AIDS. 9th meeting of the European Society of Gene therapy, Antalya, Turkey, 2001. J. van Griensven, R. Zachariah, F. Rasschaert, E.F. Atté, T. Reid. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir. Trans R Soc Trop Med Hyg, 101: 793-798, 2008. doi:10.1016/j.trstmh.2008.08.015 • J. van Griensven, L. De Naeyer, J Uwera, A. Asiimwe, C. Gazille, T. Reid. Success with antiretroviral treatment for children in Kigali, Rwanda: Experience with health center/nurse-based care. BMC Pediatrics, 8: 39, 2008. J. van Griensven, R.Zachariah. Increased baseline body weight is a risk factor associated with virological failure while on antiretroviral treatment. JAIDS, 48:631-633, 2008. Médecins Sans Frontières. Antiretroviral therapy in primary health care: scaling-up in two health centers in Kigali, Rwanda. MSF, 2007. • J. Van Griensven, E.F. Atté, T. Reid. Symptomatic hyperlactatemia: lessons learned using a point-of-care device in a health center/nurse-based antiretroviral program in Rwanda. Clin Infect Dis, 46: 320-322, 2008. J. van Griensven, R. Zachariah, F. Rasschaert, T. Reid. Discordant immunologic and virologic responses to antiretroviral therapy and associated mortality in a large treatment program in Rwanda. JAIDS (accepted for publication). F. Shumbusho, J. van Griensven, D. Lowrance, I. Turate, M. Weaver, J. Price, A. Binagwaho. Task Shifting to Achieve Universal Access: Nurse-Centered Antiretroviral Treatment Services at Rural Health Centers in Rwanda. Submitted for publication. C.A. Peltier, G.F. Ndayisaba, P. Lepage, J. van Griensven, V. Leroy MD, C. Omes, P.C. Ndimubanzi, O. Courteille, A. Asiimwe, V. Arendt. Nine-month field efficacy of two interventions to prevent mother-to-child postnatal transmission of HIV-1: formula feeding or breastfeeding with maternal antiretroviral therapy. The AMATA cohort study in Rwanda. Submitted for publication. • J. van Griensven, L. De Naeyer, T. Mushi, S. Obajiro, D. Gashumba, C. Gazille, R. Zacharíah. High prevalence of lipoatrophy on stavudine containing first line antiretroviral therapy in Rwanda. Trans R Soc Trop Med Hyg, 101: 793-798, 2007. • J. van Griensven, X. Zhan, B. Van Maele, W. Pluymers, M. Michiels, E. De Clercq, P. Cherepanov and Z. Debyser. Expression of HIV-1 integrase in human cells inhibits HIV-1 replication. J. of Gene Medicine, 6(3): 268-277, 2004. • J. van Griensven, E. Declercq and Z. Debyser. Stem cell-based gene therapy for AIDS: A Review. AIDS Rev, 7(1): 44-55, 2005. • Z. Debyser and J. van Griensven. HIV entry as target for the gene therapy of HIV Infection in Viral entry and the pathogenesis of AIDS, edited by J. Este and B. Clotet, 2001. • J. van Griensven, R. Zachariah, F. Rasschaert, A. Asiimwe, E.F. Atté, T. Reid. Discordant responses to antiretroviral treatment: prevalence, risk factors and associated mortality in Rwanda. 17th International AIDS Conference, Mexico, August 2008. • J. van Griensven, R. Zachariah, F. Rasschaert, E.F. Atté, T. Reid. Weight evolution in patients after stavudine substitution for lipoatrophy in Rwanda: Comparison of zidovudine with tenofovir/abacavir. 17th International AIDS Conference, Mexico, August 2008. • J. van Griensven, R. Zachariah, F. Rasschaert, A. Asiimwe, E.F. Atté, T. Reid. Risk factors for hepatotoxicity of nevirapine-containing antiretroviral drug regimens in a large antiretroviral treatment program in Rwanda. 17th International AIDS Conference, Mexico, August 2008. • J. van Griensven, R. Zachariah, F. Rasschaert, A. Asiimwe, E.F. Atté, T. Reid. Toxicity of stavudine- and nevirapine-containing antiretroviral treatment regimens: Incidence and risk factors after three years in a large cohort in Rwanda. 17th International AIDS Conference, Mexico, August 2008. • J. van Griensven, R. Zachariah, F. Rasschaert, E.F. Atté, T. Reid. Increased baseline body weight is a risk factor associated with virological failure while on antiretroviral treatment. 17th International AIDS Conference, Mexico, August 2008. • J. van Griensven, R. Zachariah, F. Rasschaert, E.F. Atté, T. Reid. A viral load of 10.000 copies/ml as threshold for antiretroviral treatment switch: Risk of immunological deterioration in Rwanda. 17th International AIDS Conference, Mexico, August 2008. • Johan van Griensven, Ann Corthouts, Edi F Atté and Janet Alonso. Symptomatic Lactic Acidaemia on Stavudine-containing ART: Clinical Features of 20 Cases and Risk Factor Assessment. PEPFAR International HIV Implementers Meeting, Rwanda, June 2007. • J. van Griensven, L. De Naeyer, T. Mushi, C. Gazille and R. Zachariah. How common is Lipodystrophy after at least 1 year of WHO First Line Antiretroviral Treatment in Kigali, Rwanda. 16th International AIDS Conference, Toronto, August 2006 [Abstract 140]. • J. van Griensven, T. Mushi , S. Ubarijoro and L. De Naeyer. Prevalence of lipodystrophy after 1 year of World Health Organization first line antiretroviral treatment in Kigali, Rwanda. 13thconference on Retroviruses and Opportunistic Infections, Denver, February 2006 [Abstract 560a]. • J. van Griensven, B. Van Maele, E. De Clercq and Z. Debyser. The HIV-1 cPPT/CTS Fragment Mediates Efficient Transgene Expression of Lentiviral Vectors. 10th conference on Retroviruses and Opportunistic Infections, Boston, February 2003. • L. De Naeyer, J. van Griensven, S. Ubarijoro, T. Mushi, G. Ntabashwa, C. Gazille and Rony Zachariah. HAART can be provided safely in African HIV positive children: analysis of patients in 2 urban health centres in Kigali. 16th International AIDS Conference, Toronto, August 2006 [Abstract 242]. • L. De Naeyer, J. van Griensven, S. Ubarijoro, T. Mushi, C. Gazille and R. Zachariah. CD4+ absolute count might not be a good parameter to assess immunosuppression in HIV infected children older than 5 years in Rwanda. 16th International AIDS Conference, Toronto, August 2006. • L. De Naeyer, J. van Griensven, S. Ubarijoro, T. Mushi, G. Ntabashwa, C. Gazille and Rony Zachariah. Immunological characteristics of pregnant women in an urban health centre in Kigali, Rwanda. 16th International AIDS Conference, Toronto, August 2006. • G. Diemer, J. van Griensven, E. De Clercq and Z. Debyser. Transduction Efficiency of HIV-1 derived Lentiviral Vectors in T-cell lines, Macrophages and Hematopoietic cells. 5th Annual meeting of the American Society of Gene Therapy, Seattle, 2001. • Johan van Griensven, Ann Corthouts, Edi F Atté and Janet Alonso. High efficacy of first- line ART regimens in a health-centre based ART program: virological outcomes in 1000 patients after > 1 year of treatment. Third national HIV research conference, Rwanda, March 2007. • Jeannine Uwera, Jeanne d'Arc Nyirajyambere, Joséphine Mukamuganga, Claire Gazille, Janet Alonso and Johan van Griensven. Groupes de soutien pour enfants séropositifs: participation active des enfants dans leur maladie. Third national HIV research conference, Rwanda, March 2007. • Jeannine Uwera, Jeanne d'Arc Nyirajyambere, Joséphine Mukamuganga, Claire Gazille, Janet Alonso and Johan van Griensven. Psychosocial support as a key to successful scaling up of HAART in children. Third national HIV research conference, Rwanda, March 2007. • J. van Griensven, T. Mushi, S. Ubarijoro, C. Gazille and L. De Naeyer. Twenty one months experience of HAART in adults: cohort analysis in 2 urban health centres in Kigali. Second National HIV Research Conference, Rwanda, 2006. • J. van Griensven, T. Mushi, S. Ubarijoro, C. Gazille and L. De Naeyer. Hospitalisation characteristics in two health care centres involved in scaling-up of ART. Second National HIV Research Conference, Rwanda, 2006. • J. van Griensven, T. Mushi, S. Ubarijoro, C. Gazille and L. De Naeyer. HIV-1 associated neuromuscular weakness syndrome in Kigali, Rwanda. Second National HIV Research Conference, Rwanda, 2006. • J. van Griensven, T. Mushi, C. Gazille and L. De Naeyer. Prevalence and characterization of lipoatrophy after 1 year of first line antiretroviral treatment. Second National HIV Research Conference, Rwanda, 2006. • L. De Naeyer, S. Ubarijoro ,T. Mushi, C. Gazille and J. van Griensven. Evaluation of evolution of weight as indicator of an ARV programme before ART (during co-trimoxazole prophylaxis) and while on ART. Second National HIV Research Conference, Rwanda, 2006.

Source: http://www.inbevbailletlatour.com/media/misc_media/CV%20Johan%20Van%20Griensven%20ITG%202008.pdf